WEGOVY
LaunchNDAORALTABLET
Approved
Dec 2025
Lifecycle
Launch
Competitive Pressure
0/100
Clinical Trials
8
Data completeness
6/8 — Strong
WEGOVY by Novo Nordisk is glp-1 analogue with 94% sequence homology to human glp-1. Approved for combination with a reduced calorie diet, increased physical activity: • to reduce the risk of major adverse cv events (cv death, non-fatal myocardial infarction and 4 more indications. First approved in 2025.
Drug data last refreshed 18h ago · AI intelligence enriched 6d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
WEGOVY is an oral small-molecule tablet developed by Novo Nordisk, approved in December 2025. The indication and mechanism of action are not disclosed in available data. Based on the brand name and route, this appears to be a novel formulation entering the market during an active launch phase.
$0.2MPart D
Growth12.4 years to LOEEarly commercial performance shows minimal Part D uptake (142 claims, $200K), suggesting either very recent market entry or limited penetration; commercial teams should anticipate significant expansion and hiring.
Mechanism of Action
GLP-1 analogue with 94% sequence homology to human GLP-1. Semaglutide acts as a GLP-1 receptor agonist that selectively binds to and activates the GLP-1 receptor, the target for native GLP-1. GLP-1 is a physiological regulator of appetite and caloric intake, and the GLP-1 receptor is present in…
Indications (7)
Worked on WEGOVY at Novo Nordisk? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.